Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Cost of RevenueEBIATGross ProfitLeasesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsReceivables - NetShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Niagen Bioscience (NAGE) Cost of Revenue (2016 - 2025)

Niagen Bioscience (NAGE) has disclosed Cost of Revenue for 16 consecutive years, with $10.4 million as the latest value for Q4 2025.

  • Quarterly Cost of Revenue rose 19.48% to $10.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $35.8 million through Dec 2025, up 21.62% year-over-year, with the annual reading at $35.5 million for FY2025, 20.49% up from the prior year.
  • Cost of Revenue for Q4 2025 was $10.4 million at Niagen Bioscience, down from $12.1 million in the prior quarter.
  • The five-year high for Cost of Revenue was $12.1 million in Q3 2025, with the low at $2.5 million in Q1 2025.
  • Average Cost of Revenue over 5 years is $7.2 million, with a median of $6.7 million recorded in 2021.
  • Peak annual rise in Cost of Revenue hit 71.18% in 2025, while the deepest fall reached 63.23% in 2025.
  • Over 5 years, Cost of Revenue stood at $6.9 million in 2021, then decreased by 10.22% to $6.2 million in 2022, then increased by 5.38% to $6.5 million in 2023, then skyrocketed by 33.68% to $8.7 million in 2024, then increased by 19.48% to $10.4 million in 2025.
  • According to Business Quant data, Cost of Revenue over the past three periods came in at $10.4 million, $12.1 million, and $10.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.